News

Roel van den Akker examines how the industry might evolve its trade, distribution, and payer strategies to scale GLP-1s for mass demand.

Anthony “TJ” Rizzo explains what makes an effective supply chain partnership, and how tech can be deployed alongside human experience.

In today’s Pharma Pulse, Walgreens reshapes pharmacist roles, pharmacies expand injectable access, GoodRx and Eli Lilly broaden GLP-1 access, radiopharma investment grows, and AbbVie signs a $745 million Haisco licensing deal.

Richard Harrop shares how pharma can strike a balance between performance, sustainability, and resilience in packaging design.

Seamus Keane discusses resilient supply chain design ahead of his panel at LogiPharma 2026.

Ahead of his presentation at LogiPharma 2026, Anthony “TJ” Rizzo discusses how automation and real-time monitoring can be deployed in supply chains.

Roel van den Akker evaluates how blockbuster GLP-1s may shift broader commercialization trends.

In a Q&A, Traci Miller discusses the evolving role of hub services as well as their commercial value.

Jessica Ledesma explores how hospital pharmacies are adopting autonomous cold storage to protect high-value medications.

Mastering the PSMF is critical for inspection readiness, as it provides regulators an early look at your pharmacovigilance system's compliance.

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

Laura Blair discusses what makes enrollment friction, and how the right balance of AI and human support can improve hub utilization and speed to therapy.

In this week’s Pharma Pulse, tariffs reshape drug supply, a fragile ceasefire tests global pharma, Wegovy goes higher-dose, and patients still can't get appointments fast enough.

A 14-day US-Iran ceasefire is expected to ease pressure on the Strait of Hormuz, offering a reprieve for global pharma supply chains.

Laura Blair discusses how DTP models make manufacturers rethink traditional access and distribution strategies.

Emily Gallo explains how end-to-end visibility and data integration transform pharma supply chains from reactive cost centers into resilient assets.

Manasi Salgaonkar examines how accurate class of trade research enables precise pricing, contract eligibility, and compliance.

Anthony Bianciella explains how rare disease brands lose patients because journey maps prioritize prescribing intent over the complex, unfamiliar logistics of post-diagnosis access.

Post-approval changes are overwhelming pharma ops teams. Here's why lifecycle change management has become one of the industry's most consequential and overlooked operational risks.

Pharma companies could face 100% tariffs under new US rules, with relief available for those prioritizing onshore manufacturing or pricing concessions.

Emily Gallo, SVP of OptiFreight® Logistics at Cardinal Health, discusses how predictive analytics and actionable benchmarking bridge the data-to-decision gap in pharma logistics.

In today’s Pharma Pulse, Shionogi acquires global rights to the ALS treatment Radicava, and experts monitor drug supply chains as the U.S.-Iran conflict drives up logistics costs.

Michael Oleksiw says loneliness and behavior gaps drive prescription drop-offs, making early, personalized support critical to adherence.

In Pharma Pulse, Foundayo’s record 50-day FDA approval and the threat of pharmacy data consolidation to independent pharmacies.

Traci Miller, senior director of Access and Patient Support at Cardinal Health Sonexus, explains how hub data helps pharma companies shift from reactive firefighting to proactive access optimization.

Eli Lilly’s newest GLP-1, Foundayo (orforglipron), is the first FDA-approved weight loss pill that can be taken without food or water restrictions.